Perceptive Advisors Llc bought $7.5M of Immatics (IMTX)
Executed Aug 26, disclosed Aug 27, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Aug 27), the stock returned -10.6% (delay-adjusted); from the execution session (Aug 26), -9.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Perceptive Advisors Llc (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (1 purchase, 1 sale), most often in ACRV. Across 1 priced purchase filing, the average 21-session return was -9.7% from execution and -10.6% from disclosure (delay-adjusted; derived). The largest single filing was $7.5M of IMTX (863,060 sh × $8.69, as filed), executed Aug 26.
Healthcare · Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunoth…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→